This study will examine the efficacy and safety of trastuzumab deruxtecan compared with trastuzumab emtansine in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study Of Trastuzumab Deruxtecan (T-Dxd) Versus Trastuzumab Emtansine (T-Dm1) In Subjects With High-Risk Her2-Positive Primary Breast Cancer Who Have Residual Invasive Disease In Breast Or Axillary Lymph Nodes Following Neoadjuvant Therapy.
Early Her2+ breast cancer with residual disease at surgery.
Treatment is T-Dxd vs T-Dm1 comparing them directly which treatment is better. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
For more regarding this clinical trial click here.